1. Home
  2. AUPH vs RLX Comparison

AUPH vs RLX Comparison

Compare AUPH & RLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aurinia Pharmaceuticals Inc

AUPH

Aurinia Pharmaceuticals Inc

N/A

Current Price

$14.88

Market Cap

2.2B

Sector

Health Care

ML Signal

N/A

Logo RLX Technology Inc. each representing the right to receive one (1) ordinary share

RLX

RLX Technology Inc. each representing the right to receive one (1) ordinary share

N/A

Current Price

$1.47

Market Cap

2.1B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
AUPH
RLX
Founded
1993
2018
Country
Canada
China
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medicinal Chemicals and Botanical Products
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.2B
2.1B
IPO Year
2014
2020

Fundamental Metrics

Financial Performance
Metric
AUPH
RLX
Price
$14.88
$1.47
Analyst Decision
Buy
Strong Buy
Analyst Count
6
6
Target Price
★ $18.50
$2.78
AVG Volume (30 Days)
819.4K
★ 1.3M
Earning Date
10-30-2026
11-20-2026
Dividend Yield
N/A
★ 7.53%
EPS Growth
N/A
N/A
EPS
★ 0.76
N/A
Revenue
★ $283,055,000.00
N/A
Revenue This Year
$16.65
$62.88
Revenue Next Year
$17.73
$23.93
P/E Ratio
★ $19.89
$28.09
Revenue Growth
N/A
N/A
52 Week Low
$13.52
$1.45
52 Week High
$19.25
$2.55

Technical Indicators

Market Signals
Indicator
AUPH
RLX
Relative Strength Index (RSI) 32.23 27.35
Support Level $14.76 N/A
Resistance Level $15.15 $2.08
Average True Range (ATR) 0.53 0.05
MACD -0.19 -0.01
Stochastic Oscillator 4.44 23.21

Price Performance

Historical Comparison
AUPH
RLX

About AUPH Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

About RLX RLX Technology Inc. each representing the right to receive one (1) ordinary share

RLX Technology Inc is engaged in the manufacturing of e-vapor products for adult smokers. It has an integrated offline distribution and "Branded store plus" retail model tailored to China's e-vapor market. The company has two reportable segments, Core Markets and Europe Acquisition. The majority of the revenue is earn from Core Markets segment.

Share on Social Networks: